Polycyclo-carbocyclic Ring System Bonded Directly To The Six-membered Hetero Ring (e.g., Quinophthalones, Etc.) Patents (Class 546/154)
  • Patent number: 8716421
    Abstract: This invention discloses and claims a series of polycyclic monomers and polymers useful in the production of optical waveguides. The polymers of the invention comprise one or more repeating units represented by the formula (IV): Wherein m, X, R1 and R2 are as defined herein. The films formed from the polymers of this invention exhibit significant changes in refractive index (greater than or equal to 0.5%) after exposure to suitable actinic or thermal energy thereby having superior optical transmission performance, which is of importance for modern optical applications such as wave guiding and optical data storage.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: May 6, 2014
    Assignees: Promerus, LLC, Sumitomo Bakelite Co., Ltd
    Inventors: Kazuyoshi Fujita, Nanae Kawate, Mari Ueda, Larry F Rhodes
  • Publication number: 20140121240
    Abstract: Provided is a novel pharmaceutical composition (antipruritic agent) that is useful for prophylaxis or treatment of itch in conditions such as dermal pruritus. More specifically, provided is a pharmaceutical composition (antipruritic agent) for treatment of itch comprising as an active ingredient a naphthalene compound of the following formula (I): wherein the ring A is a heterocyclic group of the following formula: a hydrate thereof or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 26, 2012
    Publication date: May 1, 2014
    Applicants: MARUHO CO., LTD., MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Ryoko Oono, Hiroko Kido
  • Publication number: 20140038883
    Abstract: The present invention relates to compounds of formula (I), where R1 and R2, identical or different, are each independently a hydrogen atom or a non-substituted or substituted (C1-C12) alkyl group; R3 is a hydrogen atom or a non-substituted or substituted (C1-C6) alkyl group; R4 is a non-substituted or substituted (C1-C12) alkyl group or an aryl or heteroaryl group, said aryl and heteroaryl groups being non-substituted or substituted; and R5 is a non-substituted or substituted (C1-C12) alkyl group; or R4 and R5 are bonded to one another by a saturated hydrocarbon chain having 3 or 4 carbon atoms, optionally in hydrated form or in the form of a salt that is acceptable for being administered to animals or plants, for the use thereof as a potentiator of the effect of an antimicrobial agent or for the use thereof as an antimicrobial agent.
    Type: Application
    Filed: January 27, 2012
    Publication date: February 6, 2014
    Applicants: UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE JOSEPH FOURIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, HOSPICES CIVIL DE LYON
    Inventors: Anne Doleans-Jordheim, Jean Freney, Charles Dumontet, Ahcene Boumend Jel, Jean-Baptiste Veron, Yung-Sing Wong
  • Patent number: 8598204
    Abstract: The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: December 3, 2013
    Assignee: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Ishtiyaque Ahmad, Pradeep Jayarajan, Nagaraj Vishwottam Kandikere, Anil Karbhari Shinde, Rama Sastri Kambhampati, Gopinadh Bhyrapuneni, Jyothsna Ravula, Sriramachandra Murthy Patnala, Venkateswarlu Jasti
  • Patent number: 8529803
    Abstract: A curable coloring composition includes a quinophthalone dye of Formula (1). A color filter employing the composition, a method for producing the color filter, and a quinophthalone dye of Formula (2) are also described. The curable coloring composition and color filter have good color hue, high transmittance properties, high light fastness and heat fastness, and excellent stability over time and solvent resistance.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: September 10, 2013
    Assignee: FUJIFILM Corporation
    Inventors: Yoshihiko Fujie, Yuuki Mizukawa, Shinichi Kanna, Kazuya Oota
  • Patent number: 8299094
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: October 30, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen
  • Publication number: 20120112142
    Abstract: To provide a curable coloring composition that has good color hue, high transmittance properties, high light fastness and heat fastness, and excellent stability over time and solvent resistance after curing, a color filter that has good color hue, high transmittance properties, and excellent light fastness, heat fastness, and solvent resistance, and is compatible with high resolution, and a method for producing same. A curable coloring composition that includes at least one type of quinophthalone dye represented by Formula (1), a color filter employing the curable coloring composition, a method for producing the color filter, and a quinophthalone dye represented by Formula (2).
    Type: Application
    Filed: March 19, 2010
    Publication date: May 10, 2012
    Applicant: FUJIFILM CORPORATION
    Inventors: Yoshihiko Fujie, Yuuki Mizukawa, Shinichi Kanna, Kazuya Oota
  • Patent number: 8153800
    Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7 or —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nit
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: April 10, 2012
    Assignees: Tibotec Pharmaceuticals Ltd., Medivar AB
    Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Karl Magnus Nilsson, Bengt Bertril Samuelsson, Asa Annica Kristina Rosenquist
  • Patent number: 7674801
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: March 9, 2010
    Assignee: AstraZeneca AB
    Inventors: Gregory Steven Basarab, Shanta Bist, John Irvin Manchester, Brian Sherer
  • Patent number: 7514557
    Abstract: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: April 7, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Rogelio Perez Frutos, Nizar Haddad, Suresh R. Kapadia, Jon Charles Lorenz, Anjan Saha, Chris Hugh Senanayake, Xudong Wei
  • Publication number: 20090044350
    Abstract: ?-Form of the dye of the formula (I) production of the ?-form, which is stable to dyeing, and its use for dyeing and printing textile materials composed of polyester and/or cellulose esters or blend fabrics of these materials with wool or cellulose.
    Type: Application
    Filed: August 2, 2005
    Publication date: February 19, 2009
    Applicant: DyStar Textilfarben GmbH & Co. Deutschland KG
    Inventor: Hartwig Jordan
  • Publication number: 20080274107
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: April 21, 2008
    Publication date: November 6, 2008
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Publication number: 20080242700
    Abstract: The present teachings relate to compounds of formula I: wherein the constituent variables are defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating selectin mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.
    Type: Application
    Filed: March 28, 2008
    Publication date: October 2, 2008
    Applicant: Wyeth
    Inventors: Neelu Kaila, Adrian Huang, Patricia Ward Bedard
  • Publication number: 20070205412
    Abstract: The present invention provides a novel anthracene derivative and an organic electronic device using the same. The organic electronic device according to the present invention shows excellent characteristics in efficiency, drive voltage, and life time.
    Type: Application
    Filed: March 6, 2007
    Publication date: September 6, 2007
    Inventors: Jae-Soon Bae, Dae-Woong Lee, Dong-Hoon Lee, Jun-Gi Jang, Sang-Young Jeon, Ji-Eun Kim
  • Patent number: 7186840
    Abstract: This invention relates to compounds, which are generally anti-inflammatory and analgesic compounds, and which are represented by Formula I: wherein A is a CH2, CH(OH), C(O), C?NOR4, NR5, O, S, S(O), or S(O)2, and the other substituents are as defined in the specification; or prodrugs, individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: March 6, 2007
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, Woongki Kim, David Bernard Smith, Kevin L. McLaren
  • Patent number: 6964966
    Abstract: This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: November 15, 2005
    Assignee: Wockhardt Limited
    Inventors: Noel John De Souza, Mahesh Vithalbhai Patel, Prasad Keshav Deshpande, Shiv Kumar Agarwal, Shrikant V. Gupte, Dilip J. Upadhyay, Satish B. Bhawsar, Rupinder K. Beri, Kandepu Sreenivas, Sheela Chandrasekharan Nair, Milind Chintaman Shukla, Yati Chugh, Nitin Shetty, Ravindra D. Yeole, M. Madhav Reddy
  • Patent number: 6878713
    Abstract: This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: April 12, 2005
    Assignee: Wockhardt Limited
    Inventors: Noel John De Souza, Mahesh Vithalbhai Patel, Prasad Keshav Deshpande, Shiv Kumar Agarwal, Kandepu Sreenivas, Sheela Chandrasekharan Nair, Yati Chugh, Milind Chintaman Shukla
  • Patent number: 6878722
    Abstract: The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: April 12, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey Allen Campbell, Stanley D'Andrea, Andrew Good, Jianqing Li, Fiona Mcphee, Amy Ripka, Paul Michael Scola, Yong Tu
  • Patent number: 6869964
    Abstract: The present invention relates to tripeptide compounds, compositions containing such compounds and methods for using such compounds for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: March 22, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey Allen Campbell, Andrew Charles Good
  • Patent number: 6849116
    Abstract: Quinophthalone derivatives have the general formula I where R1, R2, R3 and R5 are independently hydrogen, halogen or C1-C4-alkyl; R4 is —SO3H, —SO3+N+R6R7R8R9, —SO2NR6R7, —CH2NR6R7, —CH2R10, —COOH, —COO?N+R6R7R8R9, —COOR11, —COR11, —NO2 or C1-C4-alkyl; R6, R7, R8 and R9 are independently hydrogen; C1-C22-alkyl or C2-C22-alkenyl whose carbon chains may be interrupted by one or more moieties selected from the group consisting of —O—, —S—, —NR12—, —CO— and —SO2— and/or which may each be mono- or polysubstituted by hydroxyl, halogen, aryl, C1-C4-alkoxy and/or acetyl; C3-C8-cycloalkyl whose carbon skeleton may be interrupted by one or more moieties selected from the group consisting of —O—, —S—, —NR12— and —CO— and/or which may be mono- or polysubstituted by hydroxyl, halogen, aryl, C1-C4-alkoxy and/or acetyl; dehydroabietyl or aryl; R6 and R7 or R6, R7 and R8 are together a 5- to 7-membered cyclic radical which includes the nitrogen atom and may include further heteroatoms; R10 is R11 is alkyl R6; R12 is
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: February 1, 2005
    Assignee: BASF Aktiengesellschaft
    Inventors: Jianing He, Manfred Schröck
  • Patent number: 6844357
    Abstract: The present invention relates to compounds of formulas 1 and 2 wherein R1, R2, R4, R5, R6, R7, R8, R10 and Z are as defined herein. The present invention also relates to pharmaceutical compositions containing the above compounds and to methods of treating hyperproliferative disorders, such as cancer, in a mammal by administering the above compounds.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: January 18, 2005
    Assignee: Pfizer Inc.
    Inventor: Bingwei V. Yang
  • Patent number: 6844439
    Abstract: A process for the preparation of 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolinone which comprises reacting 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone with a C6-8alkyllithium compound, 1-methylimidazole and a tri(C4-6alkyl)silyl halide to obtain better yields of the above product.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: January 18, 2005
    Assignee: Jansen Pharmaceutica, NV
    Inventors: Walter Ferdinand Maria Filliers, Rudy Laurent Maria Broeckx, Stefan Marcel Herman Leurs
  • Patent number: 6833455
    Abstract: Disclosed herein are bridged perinones/quinophthalones of the general formula (I) or tautomeric forms thereof where X1, X2, Ar1 Ar2 and B are as described herein and are particularly characterized in that the bridging B is a radical of the formula —T1—W—T2—, where T1 and T2 are independently O or S and W is alkylene, especially C1-C6-alkylene, C6-C10-arylene, especially phenylene or cycloalkylene, which are each optionally substituted or is the radical of the formula (a) where the phenyl rings are optionally substituted and A is a radical of the formula O, S, SO, SO2 or CO, optionally substituted alkylene, or optionally substituted cycloalkylene, said alkylene or cycloalkylene being attached to the adjacent phenyl rings itself or else via its substitutents, or W is a radical of the formulae where s and t are independently from 1 to 6, the ends of the radical B each being attached to an aromatic carbon atom of the two radicals Ar1
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: December 21, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Christoph Thiebes, Josef-Walter Stawitz, Ulrich Feldhues
  • Patent number: 6806276
    Abstract: A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: October 19, 2004
    Assignee: Japan Tobacco Inc.
    Inventors: Takashi Inaba, Tetsudo Kaya, Hiroyuki Iwamura
  • Patent number: 6762194
    Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: July 13, 2004
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Eliza Jazan
  • Publication number: 20030139498
    Abstract: Disclosed herein are bridged perinones/quinophthalones of the general formula (I) or tautomeric forms thereof 1
    Type: Application
    Filed: November 22, 2002
    Publication date: July 24, 2003
    Inventors: Christoph Thiebes, Josef-Walter Stawitz, Ulrich Feldhues
  • Patent number: 6509352
    Abstract: A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]:   (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: January 21, 2003
    Assignee: Japan Tobacco Inc.
    Inventors: Takashi Inaba, Tetsudo Kaya, Hiroyuki Iwamura
  • Patent number: 6486143
    Abstract: The invention relates to a compound of formula (I): wherein: R1 represents halogen or a group CF3, R2 represents hydrogen or alkyl or cycloalkyl, R3 is as defined in the description, R4 and R5 represent hydrogen or alkyl, cycloalkyl, aryl or arylalkyl a group Medicaments.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: November 26, 2002
    Assignee: Les Laboratoires Servier
    Inventors: Alex Cordi, Patrice Desos, Pierre Lestage
  • Patent number: 6448254
    Abstract: Amides of the general formula I and their tautomeric and isomeric forms, possible enantiomeric and diastereomeric forms, as well as possible physiologically tolerable salts, in which the variables have the following meanings: R1 [sic] can be C1-C6-alkyl, phenyl, naphthyl, quinolyl, pyridyl, pyrimidyl, pyridazyl, quinazolyl and quinoxalyl, where the rings can additionally be substituted by up to 2 radicals R4 [sic], and R2 [sic] is —(CH2)m—R8 [sic], where R8 [sic] can be phenyl, cyclohexyl- or indolyl and m=1 to 6, and X is a bond, —CH2—, —CH2CH2—, —CH═CH—, —C≡C—, —CONH—, —SO2NH— [sic], and and [sic] R1—X [sic] together are also  and R3 [sic] is hydrogen and CO—NR6R7 [sic], R4 [sic] is hydrogen, C1-C4-alkyl [sic], which is branched an
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: September 10, 2002
    Assignee: Abbott Laboratories
    Inventors: Wilfried Lubisch, Achim Möller, Hans-Jörg Treiber, Monika Knopp
  • Patent number: 6440995
    Abstract: Phenyl substituted quinolin 4-yl derivatives and pharmaceutical compositions with activity as NMDA-receptor subtype selective blockers. The compounds of the invention modulate neuronal activity and plasticity.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: August 27, 2002
    Assignee: Hoffman-La Roche Inc.
    Inventors: Alexander Alanine, Serge Burner, Bernd Buettelmann, Marie-Paule Heitz Neidhart, Georg Jaeschke, Emmanuel Pinard, René Wyler
  • Patent number: 6420555
    Abstract: The present invention is directed to imidazolyl derivatives of formula (I), wherein the variables are defined in the specification, which are useful as prenyl transferase inhibitors.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: July 16, 2002
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen
  • Publication number: 20020065401
    Abstract: The invention relates to novel soluble pigment precursors possessing not only higher thermal stability but also improved solubility characteristics and to a process for mass coloration of high temperature polymers that utilizes these novel soluble pigment precursors.
    Type: Application
    Filed: November 20, 2001
    Publication date: May 30, 2002
    Inventors: Leonhard Feiler, Zhimin Hao
  • Patent number: 6329389
    Abstract: The present invention provides a compound of the formula: wherein Ar represents an aromatic group which may be substituted; X represents methylene, S, SO, SO2 or CO; Y represents a spacer having a main chain of 2 to 5 atoms; n represents an integer of 1 to 5; i) R1 and R2 each represents a hydrogen atom or a lower alkyl which may be substituted, ii) R1 and R2 form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or iii) R1 or R2 together with —(CH2)n—N═ form, bonded to a component atom of Ring B, a spiro-ring which may be substituted; Ring A represents an aromatic ring which may be substituted; Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl, with a proviso that X represents S, SO, SO2 or CO when Ring A has as a substituent a group represented by the formula: —NHCOR11 where R11 represents alkyl, alkoxyalkyl, alkylthio
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: December 11, 2001
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Nobuhiro Suzuki, Kaneyoshi Kato, Shiro Takekawa, Jun Terauchi, Satoshi Endo
  • Patent number: 6274728
    Abstract: Compounds of formula A(B)x  (I), wherein x is an integer from 1 to 8, A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, indanthrone, isoindolinone, isoindoline, dioxazine, azo, phthalocyanine or diketopyrrolopyrrole series that is bonded to x groups B via one or more hetero atoms, those hetero atoms being selected from the group consisting of N, O and S and forming part of the radical A, each group B independently of any other(s) is hydrogen or a group of the formula  at least one group B being a group of the formula The compounds according to the invention are used in high-molecular-weight organic materials, thermo-, photo- or chemo-sensitive recording materials, light-sensitive negative or positive resist compositions, ink compositions for ink-jet printing and color tapes for thermal transfer printing.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: August 14, 2001
    Assignee: Ciba Specialty Chemicals Corp.
    Inventors: Véronique Hall-Goulle, Aline Bize
  • Patent number: 6172084
    Abstract: The present invention provides methods and pharmaceutical preparations that inhibit the growth of bacterial microorganisms. Additionally, the present invention provides methods and pharmaceutical preparations that kill bacterial microorganisms.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: January 9, 2001
    Assignee: Sepracor, Inc.
    Inventors: Gregory D. Cuny, James R. Hauske, Donald L. Heefner, Michael Z. Hoemann, Gnanasambandam Kumaravel, Anita Melikian-Badalian, Richard F. Rossi
  • Patent number: 6169096
    Abstract: This invention comprises the novel compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula —Alk1—C(═O)—R9, —Alk1—S(O)—R9 or —Alk1—S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono-or di(C1-6alkyl)aminoC1-6alkyloxy,Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: January 2, 2001
    Assignee: Janssen Pharmacaeutic N.V.
    Inventors: Marc Gaston Venet, Patrick Ren{acute over (e)} Angibaud, Philippe Muller, G{acute over (e)}rard Charles Sanz
  • Patent number: 6143895
    Abstract: The present invention relates to novel tetrahydro-quinoline compounds of the following formula, libraries containing such compounds, and to the generation of such combinatorial libraries composed of such compounds: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and Y have the meanings provided.
    Type: Grant
    Filed: August 20, 1998
    Date of Patent: November 7, 2000
    Assignee: Trega Biosciences, Inc.
    Inventors: Yazhong Pei, John S. Kiely
  • Patent number: 6121452
    Abstract: The present invention relates to a process for preparing compounds of formula (I) ##STR1## wherein A completes an unsubstituted or substituted heteroaromatic ring andB completes an unsubstituted or substituted aromatic ring, by reacting a heterocyclic compound of formula (II) ##STR2## wherein A completes an unsubstituted or substituted heteroaromatic ring, with an aromatic dicarboxylic acid of formula (III) ##STR3## or an anhydride thereof, wherein B completes an unsubstituted or substituted aromatic ring, in an organic solvent in the presence of an aliphatic or aromatic alcohol that is different from both the organic solvent and compounds (I), (II), and (III).
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: September 19, 2000
    Assignee: Bayer Aktiengesellschaft
    Inventors: Dietmar Kalz, Stephan Michaelis, Karl-Heinz Reinhardt
  • Patent number: 6080757
    Abstract: A compound of the formula I ##STR1## or a pharmaceutically acceptable salt or hydrate thereof, wherein X, Y, Z and R.sup.1 to R.sup.7 are as defined herein, are inhibitors of H. pylori and therefore of use in the treatment and prevention of peptic ulcers, gastritis, dyspepsia, and gastric cancer.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: June 27, 2000
    Assignee: Pfizer Inc
    Inventor: Matthew F. Brown
  • Patent number: 6051360
    Abstract: Dyestuffs represented by the below-described formula (1), that is, dyestuffs formed of a chromophoric nucleus and a bisphenol introduced therein have excellent solubility in solvents and binder resins, and can provide color filters having excellent transmittance characteristics and durability. ##STR1## wherein Dye represents a chromophoric nucleus, X represents a direct bond or a divalent connecting group, R.sup.1 to R.sup.10 and n are defined with the provision that one of R.sup.9 and R.sup.10 has 3 or more carbon atoms.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: April 18, 2000
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Akio Karasawa, Hisato Itoh
  • Patent number: 6037350
    Abstract: This invention comprises the novel compounds of formula (I) ##STR1## wherein the dotted line represents an optional bond; X is oxygen or sulfur; R.sup.1 is hydrogen, C.sub.1-12 alkyl, Ar.sup.1, Ar.sup.2 C.sub.1-6 alkyl, quinolinylC.sub.1-6 alkyl, pyridylC.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkyloxyC.sub.1-6 alkyl, mono- or di(C.sub.1-6 alkyl)aminoC.sub.1-6 alkyl, aminoC.sub.1-6 alkyl, or a radical of formula -Alk.sup.1 -C(.dbd.O)--R.sup.9, -Alk.sup.1 -S(O)--R.sup.9 or -Alk.sup.1 -S(O).sub.2 --R.sup.9 ; R.sup.2, R.sup.3 and R.sup.16 each independently are hydrogen, hydroxy, halo, cyano, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, hydroxyC.sub.1-6 alkyloxy, C.sub.1-6 alkyloxyC.sub.1-6 alkyloxy, aminoC.sub.1-6 alkyloxy, mono- or di(C.sub.1-6 alkyl)aminoC.sub.1-6 alkyloxy, Ar.sup.1, Ar.sup.2 C.sub.1-6 alkyl, Ar.sup.2 oxy, Ar.sup.2 C.sub.1-6 alkyloxy, hydroxycarbonyl, C.sub.1-6 alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C.sub.2-6 alkenyl; R.sup.4 and R.sup.5 each independently are hydrogen, halo, Ar.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: March 14, 2000
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Marc Gaston Venet, Patrick Rene Angibaud, Philippe Muller, Gerard Charles Sanz
  • Patent number: 5968952
    Abstract: The present invention is concerned with compounds of formula (I), ##STR1## the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; R.sup.1 is hydrogen, C.sub.1-12 alkyl, Ar.sup.1, Ar.sup.2 C.sub.1-6 alkyl, quinolinylC.sub.1-6 alkyl, pyridylC.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkyloxyC.sub.1-6 alkyl, mono- or di(C.sub.1-6 alkyl)-aminoC.sub.1-6 alkyl, aminoC.sub.1-6 alkyl, or a radical of formula --Alk.sup.1 --C(.dbd.O)--R.sup.9, --Alk.sup.1 --S(O)--R.sup.9 or --Alk.sup.1 --S(O).sub.2 --R.sup.9 ; R.sup.2 and R.sup.3 each independently are hydrogen, hydroxy, halo, cyano, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, hydroxyC.sub.1-6 alkyloxy, C.sub.1-6 alkyloxy-C.sub.1-6 alkyloxy, aminoC.sub.1-6 alkyloxy, mono- or di(C.sub.1-6 alkyl)aminoC.sub.1-6 alkyloxy, Ar.sup.1, Ar.sup.2 C.sub.1-6 alkyl, Ar.sup.2 oxy, Ar.sup.2 C.sub.1-6 alkyloxy, hydroxycarbonyl, C.sub.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: October 19, 1999
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Marc Gaston Venet, Patrick Rene Angibaud, Gerard Charles Sanz, David William End
  • Patent number: 5929087
    Abstract: Compounds of formula I or formula II: ##STR1## wherein R, J, and Q have any of the values defined in the specification, and their pharmaceutically acceptable salts and related radiopharmaceuticals, have anticholinergic activity, and are useful for modulating cholinergic function in mammals. Also disclosed are pharmaceutical compositions, processes for preparing compounds of formula (I) or (II) and intermediates.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: July 27, 1999
    Assignee: Regents of the University of Minnesota
    Inventors: S. Mbua Ngale Efange, Stanley M. Parsons
  • Patent number: 5849756
    Abstract: Pharmaceutical compositions for the modulation of the immune reaction of warm blooded animals that are derivatives of the 2-oxindole-3-acetic acid or the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid are described, and whereby the derivatives can optionally be in an equilibrium with each other.The derivatives included in the pharmaceutical compositions comprise those compounds which are already described in the literature and also new compounds.Furthermore, new derivatives of the the 2-oxindole-3-acetic acid and the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid are described, particularly also the the pure antipodes of the mixture of enantiomeres of the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: December 15, 1998
    Assignee: Cerbios-Pharma SA
    Inventors: Ulrich Burger, Jean-Claude Jaton, Fabrizio Marazza, Ari Lewenstein, Francis M. Sirotnak
  • Patent number: 5780627
    Abstract: Compounds of formulaA(B).sub.x, (I),wherein x is an integer from 1 to 4,A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, isoindolinone, isoindoline, dioxazine, phthalocyanine or azo series, which radical contains x N-atoms attached to B, preferably with at least one directly adjacent or conjugated carbonyl group,B is a group of formula ##STR1## and, if x is 2, 3 or 4, may also be one, two or three hydrogen atoms. The symbols Q, R.sub.1, R.sub.2, R.sub.3, R.sub.4, X, Y, Z, m und n, are as defined in claim 1. These carbamate group-containing soluble chromophores are distinguished by outstanding solid state fluorescence in the UV range as well as the by ease with which they can be converted to the corresponding pigments in the substrate in which they are incorporated.
    Type: Grant
    Filed: July 9, 1996
    Date of Patent: July 14, 1998
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Zhimin Hao, John S. Zambounis, Abul Iqbal
  • Patent number: 5750599
    Abstract: Novel quinophthalone compounds, which are represented by the following formula (1): ##STR1## R.sub.1 -R.sub.5 each independently represents a hydrogen or halogen atom or a hydroxy, linear or branched alkyl, substituted or unsubstituted cycloalkyl, halogenated alkyl, alkoxyalkyl, alkoxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyloxy or cyano group; R.sub.6 -R.sub.17 each independently represents a hydrogen or halogen atom or a hydroxyl, alkyl, halogenated alkyl, alkoxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylcarbonyloxy or cyano group; m and n each stands for 0 or 1; and A represents a substituent, are yellow orange dyestuffs suitable for polarizing films.
    Type: Grant
    Filed: March 19, 1997
    Date of Patent: May 12, 1998
    Assignee: Mitsui Toatsu Chemicals, Inc.
    Inventors: Akira Ogiso, Rihoko Imai, Tsutami Misawa, Ryu Oi, Yoriaki Matsuzaki, Hisato Itoh
  • Patent number: 5731321
    Abstract: Novel compounds of the formula I ##STR1## in which --Y--Z--, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings as stated in the specification, and their salts show endothelin receptor antagonist properties.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: March 24, 1998
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Werner Mederski, Mathias Osswald, Dieter Dorsch, Claudia Wilm, Claus J. Schmitges, Maria Christadler
  • Patent number: 5695684
    Abstract: A mesomorphic compound represented by a formula (I) containing a quinoline-2,6-diyl skeleton is suitable as a component for a liquid crystal composition providing improved response characteristics and a high contrast. A liquid crystal device is constituted by disposing the liquid crystal composition between a pair of electrode plates. The liquid crystal device may preferably be used as a display panel constituting a liquid crystal apparatus providing good display characteristics.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: December 9, 1997
    Assignee: Canon Kabushiki Kaisha
    Inventors: Yoko Kosaka, Takao Takiguchi, Takashi Iwaki, Takeshi Togano, Shinichi Nakamura
  • Patent number: 5691322
    Abstract: Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have a quinoline or a pyridine anchor attached by means of a linker to a binding domain sidechain, which compounds inhibit the enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase.
    Type: Grant
    Filed: October 31, 1995
    Date of Patent: November 25, 1997
    Assignee: E.R. Squibb & Sons, Inc.
    Inventor: Jeffrey Adam Robl
  • Patent number: 5659039
    Abstract: Novel quinophthalone compounds, which are represented by the following formula (1): ##STR1## R.sub.1 -R.sub.5 each independently represents a hydrogen or halogen atom or a hydroxy, linear or branched alkyl, substituted or unsubstituted cycloalkyl, halogenated alkyl, alkoxyalkyl, alkoxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyloxy or cyano group; R.sub.6 -R.sub.17 each independently represents a hydrogen or halogen atom or a hydroxyl, alkyl, halogenated alkyl, alkoxy, nitro, amino, alkylamino, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylcarbonyloxy or cyano group; m and n each stands for 0 or 1; and A represents a substituent, are yellow orange dyestuffs suitable for polarizing films.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: August 19, 1997
    Assignee: Mitsui Toatsu Chemicals, Inc.
    Inventors: Akira Ogiso, Rihoko Imai, Tsutami Misawa, Ryu Oi, Yoriaki Matsuzaki, Hisato Itoh